Revance Therapeutics, Inc. (RVNC) | Investment Case

1. Company Snapshot

1.a. Company Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX.

The company has a collaboration and license agreement with Viatris Inc.to develop, manufacture, and commercialize onabotulinumtoxinA.The company was formerly known as Essentia Biosystems, Inc.

and changed its name to Revance Therapeutics, Inc.in April 2005.Revance Therapeutics, Inc.

was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Show Full description

1.b. Last Insights on RVNC

Revance Therapeutics, Inc.'s recent performance was negatively driven by a Q3 loss of $0.37 per share, exceeding the Zacks Consensus Estimate of a loss of $0.35. The company also disclosed alleged material breaches under its exclusive distribution agreement with Teoxane SA, including breaches of buffer stock and promotion efforts. This led to a notice to remedy the breaches, which may have a negative impact on the company's future performance. Additionally, the company is facing a class action lawsuit and securities fraud investigation, which may further exacerbate the negative sentiment.

1.c. Company Highlights

Last Price	3.65
Change Percentage	0.00%
Open	3.65
Previous Close	3.65
Market Cap ( Millions)	381
Volume	0
Year High	7.56
Year Low	2.3
M A 50	3.39
M A 200	4.16

FCF Yield	-21.72%
Dividend Yield	0.00%
ROE	49.59%
Debt / Equity	-296.54%
Net Debt / EBIDTA	-720.20%
Price To Book	-2.33
Price Earnings Ratio	-5.24
Price To FCF	-4.6
Price To sales	3.04
EV / EBITDA	-13.66

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Sep -09

Source: globenewswire.com

Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day

May -27

Source: https://www.prnewswire.com

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Mar -07

Source: globenewswire.com

RVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNC

Mar -04

Source: accessnewswire.com

Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)

Mar -04

Source: globenewswire.com

Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)

Mar -04

Source: accessnewswire.com

FINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit

Mar -04

Source: accessnewswire.com

Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC

Mar -04

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.36%)

6. Segments

Product

Expected Growth: 9.27%

Revance Therapeutics' 9.27% growth is driven by increasing demand for its novel neuromodulator product, Daxxify, which addresses a large unmet need in the facial aesthetics market. Strong sales momentum, expanding commercial footprint, and growing adoption by physicians and patients are key growth catalysts. Additionally, the company's strategic partnerships and investments in R&D are expected to fuel future growth.

Service

Expected Growth: 10.93%

Revance Therapeutics' 10.93% growth is driven by increasing demand for its neurotoxin-based aesthetic treatments, particularly its flagship product Daxxify, which has gained popularity among consumers seeking non-invasive facial rejuvenation. Additionally, the company's expanding commercial presence, strategic partnerships, and ongoing R&D efforts have contributed to its growth momentum.

7. Detailed Products

Daxxify

A prescription medication used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows in adults.

RHA Collection of Dermal Fillers

A line of hyaluronic acid-based dermal fillers used to restore lost volume, smooth out wrinkles, and enhance facial features.

Zypadhera

A botulinum toxin type A used to treat cervical dystonia and blepharospasm.

8. Revance Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Revance Therapeutics, Inc. operates in a highly competitive industry with many established players, which increases the threat of substitutes. However, the company's focus on developing novel treatments for rare diseases and its strong pipeline of products in development mitigate this threat to some extent.

Bargaining Power Of Customers

Revance Therapeutics, Inc. has a diverse customer base, including hospitals, clinics, and pharmacies, which reduces the bargaining power of individual customers. Additionally, the company's products are often reimbursed by insurance companies, which further reduces the bargaining power of customers.

Bargaining Power Of Suppliers

Revance Therapeutics, Inc. relies on a limited number of suppliers for raw materials and manufacturing services, which gives these suppliers some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk to some extent.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and technologies. Revance Therapeutics, Inc. faces a high threat of new entrants, particularly from smaller, more agile companies that can quickly develop and commercialize new products.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Revance Therapeutics, Inc. faces intense rivalry from established players and new entrants. The company must continually innovate and invest in research and development to stay ahead of its competitors and maintain its market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	153.04%
Debt Cost	4.04%
Equity Weight	-53.04%
Equity Cost	9.70%
WACC	1.04%
Leverage	-288.55%

11. Quality Control: Revance Therapeutics, Inc. passed 6 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Revance Therapeutics

A-Score: 4.2/10

Value: 9.0

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 1.0

Volatility: 2.7

1-Year Total Return ->

TRACON Pharmaceuticals

A-Score: 3.7/10

Value: 9.6

Growth: 6.9

Quality: 5.2

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

Unicycive Therapeutics

A-Score: 3.6/10

Value: 6.4

Growth: 4.6

Quality: 3.6

Yield: 0.0

Momentum: 6.5

Volatility: 0.7

1-Year Total Return ->

Vericel

A-Score: 3.4/10

Value: 1.0

Growth: 7.9

Quality: 6.1

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

Matinas BioPharma

A-Score: 2.8/10

Value: 7.8

Growth: 4.2

Quality: 3.2

Yield: 0.0

Momentum: 1.0

Volatility: 0.3

1-Year Total Return ->

Inovio Pharmaceuticals

A-Score: 1.9/10

Value: 6.4

Growth: 0.3

Quality: 3.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

9.12%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

1.04%

Revance Therapeutics, Inc. - US7613301099

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on RVNC

1.c. Company Highlights

Cheaper

Weak Momentum

Average Growth

Earnings Beats

Revenues Miss

Medium Volatility

Fairly Valued

Stable Momentum

Earnings Miss

Average Quality

Strong Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.36%)

6. Segments

Product

Expected Growth: 9.27%

Service

Expected Growth: 10.93%

7. Detailed Products

Daxxify

RHA Collection of Dermal Fillers

Zypadhera

8. Revance Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Revance Therapeutics, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.65$

Current Price

3.65$

Potential

0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA